Bidder-Activist Collaboration Will Continue To Evolve
On Nov. 17, 2014, Allergan Inc. announced a $66 billion merger agreement with Actavis PLC, thwarting the pending $53 billion bid for Allergan by Valeant Pharmaceuticals International Inc. Valeant had teamed...To view the full article, register now.
Already a subscriber? Click here to view full article